Soon on demand: Quarterly Focus on Hemato-Oncology | highlights in AML

October 24, 2017

  • Share this post:

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not have always sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks.eu has developed a new program format, the ‘Quarterly Focus , which brings together an expert panel and the authors of relevant, selected publications in an innovative way to explain and discuss the new data.

The selection for the first edition of Quarterly Focus on Hemato-Oncology has been made by prof. dr. Gert Ossenkoppele, VUmc Amsterdam, Netherlands. Three pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the unique possibility to gain more insight into the selected publications and to interact with the expert panel and the authors.

The expert panel consists of:

  • Prof. Gert Ossenkoppele, MD, hematologist, VUmc, Amsterdam, Netherlands;
  • Prof. Gerwin Huls, MD, hematologist, UMCG, Groningen; Netherlands;
  • Peter Valk, Ph.D., molecular biologist, Erasmus MC, Rotterdam, Netherlands.

Selected publications Quarterly Hemato-Oncology (in progress):

Midostaurin plus chemotherapy for acute myeloid leukemia with FLT mutation

N Engl J Med 2017

Prof. Richard Schlenk, MD, hematologist

 

TP53 and decitabine in AML and myelodysplastic syndromes

N Engl J Med 2016

Dr. John S. Welch, MD, Ph.D., hematologist

 

Precision Oncology in acute myeloid leukemia using a knowledge bank approach.

Nature Genetics, January 2017

Elli Papaemmanuil, Ph.D., molecular geneticist

Accreditation:

This program will be submitted for accreditation at the EBAH and Dutch NIV.

This program is editorially independent and is financially supported by Novartis and Quadia Online Video.